JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB251612

Anti-PD1 antibody [CAL15] - BSA and Azide free

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Recombinant Monoclonal PD1 antibody. Carrier free. Suitable for WB, IHC-P and reacts with Human samples. Cited in 1 publication.

View Alternative Names

CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1

3 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [CAL15] - BSA and Azide free (AB251612)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [CAL15] - BSA and Azide free (AB251612)

Immunohistochemical analysis of paraffin-embedded human tonsil tissue labeling PD1 with ab237727 at 1/1000 dilution, followed by Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Positive staining on the human tonsil is observed. Counter stained with hematoxylin.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.

The section was incubated with ab237727 for 30 mins at room temperature.

The immunostaining was performed on a Leica Biosystems BOND® RX instrument.

This data was developed using the same antibody clone in a different buffer formulation containing PBS and sodium azide (ab237727).

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [CAL15] - BSA and Azide free (AB251612)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [CAL15] - BSA and Azide free (AB251612)

Immunohistochemical analysis of paraffin-embedded human spleen tissue labeling PD1 with ab237727 at 1/1000 dilution, followed by Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Positive staining on the human spleen is observed. Counter stained with hematoxylin.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.

The section was incubated with ab237727 for 30 mins at room temperature.

The immunostaining was performed on a Leica Biosystems BOND® RX instrument.

This data was developed using the same antibody clone in a different buffer formulation containing PBS and sodium azide (ab237727).

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [CAL15] - BSA and Azide free (AB251612)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [CAL15] - BSA and Azide free (AB251612)

Formalin-fixed, paraffin-embedded human tonsil tissue stained for PD1 using ab237727 at 0.25 μg/ml dilution in immunohistochemical analysis.

This data was developed using the same antibody clone in a different buffer formulation containing PBS and sodium azide (ab237727).

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

CAL15

Isotype

IgG

Carrier free

Yes

Reacts with

Human

Applications

WB, IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Alternative Products

Primary Antibodies

AB227681

Anti-PD1 antibody [SP269]

20ul selling size|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [SP269] (AB227681)

  • 0
  • 0
Primary Antibodies

AB214421

Anti-PD1 antibody [EPR20665]

20ul selling size|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR20665] (AB214421)

  • 4
  • 3
Primary Antibodies

AB237728

Anti-PD1 antibody [CAL20]

BOND RX™ Validated|20ul selling size|RabMAb|Advanced Validation|Recombinant

Immunocytochemistry/ Immunofluorescence - Anti-PD1 antibody [CAL20] (AB237728)

  • 5
  • 1
Primary Antibodies

AB137132

Anti-PD1 antibody [EPR4877(2)]

BOND RX™ Validated|20ul selling size|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)

  • 5
  • 5

Complementary Products

Assay Kits

AB252360

Human PD-1 ELISA Kit

Recombinant|SimpleStep

ELISA - Human PD-1 ELISA Kit (AB252360)

  • 0
  • 0
Primary Antibodies

AB205921

Anti-PD-L1 antibody [28-8]

BOND RX™ Validated|20ul selling size|Recombinant|KO Validated|Advanced Validation|RabMAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [28-8] (AB205921)

  • 4
  • 15
Primary Antibodies

AB133616

Anti-CD4 antibody [EPR6855]

BOND RX™ Validated|RabMAb|Recombinant|Lab Essentials|20ul selling size|Advanced Validation

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD4 antibody [EPR6855] (AB133616)

  • 5
  • 20
Primary Antibodies

AB20034

Anti-FOXP3 antibody [236A/E7]

BOND RX™ Validated|Recombinant|Lab Essentials|Advanced Validation

Multiplex immunohistochemistry - Anti-FOXP3 antibody [236A/E7] (AB20034)

  • 4
  • 38
Primary Antibodies

AB237709

Anti-CD8 alpha antibody [CAL66]

BOND RX™ Validated|20ul selling size|RabMAb|Advanced Validation|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD8 alpha antibody [CAL66] (AB237709)

  • 5
  • 2
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICC" : {"fullname" : "Immunocytochemistry", "shortname":"ICC"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICC-species-checked": "notRecommended", "ICC-species-dilution-info": "", "ICC-species-notes": "<p></p>", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" } } }
style
left-column

Product details

ab251612 is the carrier-free version of ab237727.

Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Purification notes
Purity is greater than 99%.
Storage buffer
pH: 7.2 - 7.4 Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Do Not Freeze
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD1 also known as Programmed Cell Death Protein 1 or PDCD1 is a transmembrane protein that plays a critical role in regulating immune responses. It has a mass of approximately 55 kDa. PD1 is expressed on the surface of T cells B cells and some myeloid cells. PD1’s expression increases upon activation of these immune cells assisting in maintaining peripheral tolerance. Researchers often use PD1 mouse models and chimeric antibodies to explore the function of PD1 for experimental purposes. Antibodies such as anti-PD1 such as EH12.2H7 help in blocking PD1 interaction to study its role further.
Biological function summary

PD1 serves as an inhibitory receptor acting as a checkpoint in the immune system. It becomes part of an immune-suppressive complex when it binds with its ligands PD-L1 or PD-L2 which are expressed on various cell types including some tumor cells. This interaction suppresses the proliferation of T cells and cytokine production contributing to immune homeostasis. By controlling T cell activity PD1 limits autoimmunity but can also reduce the immune system's capability to attack cancer cells.

Pathways

PD1 functions in the immune checkpoint pathway a critical regulatory circuit in immune regulation. The engagement of PD1 with its ligands initiates a cascade that inhibits the function and proliferation of T cells through downstream SHP-2 phosphatase activity. This pathway frequently involves other regulatory proteins like CTLA-4 and is an important mechanism by which the body modulates immune responses. Related pathways often intersect with those involving T cell receptor signaling and contribute to the overall modulation of immune activity.

PD1 has a significant role in cancer and autoimmune disorders. PD1 expression can allow tumors to evade immune surveillance making PD1 a target for cancer therapies such as anti-PD1 antibodies which aim to block PD1 and restore T cell activity. The interaction of PD1 with cancer-related proteins like PD-L1 facilitates tumor immune evasion. In autoimmune disorders PD1’s regulation of immune balance can become dysregulated leading to persistent immune activation and tissue damage. Understanding PD1 and its interaction with proteins such as PD-L1 helps in developing therapeutic strategies for both cancer and autoimmune conditions.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 21276005, PubMed : 31754127, PubMed : 32184441, PubMed : 37208329). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed : 21276005, PubMed : 26602187). Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation (PubMed : 32184441). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2 : following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (PubMed : 32184441).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28951311). The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 28951311). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 22658127, PubMed : 25034862, PubMed : 25399552).
See full target information PDCD1
style
left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Cancer communications (London, England) 43:435-454 PubMed36855844

2023

Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Chaofan Liu,Xi Wang,Wan Qin,Jingyao Tu,Chunya Li,Weiheng Zhao,Li Ma,Bo Liu,Hong Qiu,Xianglin Yuan
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com